GSK-LSD1, an LSD1 inhibitor, quashes SARS-CoV-2-triggered cytokine release syndrome in-vitro.

ABSTRACT:

SUBMITTER: Hong KS 

PROVIDER: S-EPMC7670835 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature